<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39298023</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>19</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>22</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1432-0614</ISSN><JournalIssue CitedMedium="Internet"><Volume>108</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>19</Day></PubDate></JournalIssue><Title>Applied microbiology and biotechnology</Title><ISOAbbreviation>Appl Microbiol Biotechnol</ISOAbbreviation></Journal><ArticleTitle>Rifaximin ameliorates influenza A virus infection-induced lung barrier damage by regulating gut microbiota.</ArticleTitle><Pagination><StartPage>469</StartPage><MedlinePgn>469</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">469</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00253-024-13280-6</ELocationID><Abstract><AbstractText>Prior research has indicated that the gut-lung-axis can be influenced by the intestinal microbiota, thereby impacting lung immunity. Rifaximin is a broad-spectrum antibacterial drug that can maintain the homeostasis of intestinal microflora. In this study, we established an influenza A virus (IAV)-infected mice model with or without rifaximin supplementation to investigate whether rifaximin could ameliorate lung injury induced by IAV and explore the molecular mechanism involved. Our results showed that IAV caused significant weight loss and disrupted the structure of the lung and intestine. The analysis results of 16S rRNA and metabolomics indicated a notable reduction in the levels of probiotics Lachnoclostridium, Ruminococcaceae_UCG-013, and tryptophan metabolites in the fecal samples of mice infected with IAV. In contrast, supplementation with 50 mg/kg rifaximin reversed these changes, including promoting the repair of the lung barrier and increasing the abundance of Muribaculum, Papillibacter and tryptophan-related metabolites content in the feces. Additionally, rifaximin treatment increased ILC3 cell numbers, IL-22 level, and the expression of RORγ and STAT-3 protein in the lung. Furthermore, our findings demonstrated that the administration of rifaximin can mitigate damage to the intestinal barrier while enhancing the expression of AHR, IDO-1, and tight junction proteins in the small intestine. Overall, our results provided that rifaximin alleviated the imbalance in gut microbiota homeostasis induced by IAV infection and promoted the production of tryptophan-related metabolites. Tryptophan functions as a signal to facilitate the activation and movement of ILC3 cells from the intestine to the lung through the AHR/STAT3/IL-22 pathway, thereby aiding in the restoration of the barrier. KEY POINTS: • Rifaximin ameliorated IAV infection-caused lung barrier injury and induced ILC3 cell activation. • Rifaximin alleviated IAV-induced ﻿gut dysbiosis and recovered tryptophan metabolism. • Tryptophan mediates rifaximin-induced ILC3 cell activation via the AHR/STAT3/IL-22 pathway.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Zhang</LastName><ForeName>Yijia</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Laboratory of Animal Neurobiology, College of Veterinary Medicine, Nanjing Agricultural University, Nanjing, 210095, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Chen</LastName><ForeName>Yafei</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Laboratory of Animal Neurobiology, College of Veterinary Medicine, Nanjing Agricultural University, Nanjing, 210095, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xia</LastName><ForeName>Jun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute of Veterinary Medicine, Xinjiang Academy of Animal Science, Urumqi, 830013, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Li</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Laboratory of Animal Neurobiology, College of Veterinary Medicine, Nanjing Agricultural University, Nanjing, 210095, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Lifeng</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Laboratory of Animal Neurobiology, College of Veterinary Medicine, Nanjing Agricultural University, Nanjing, 210095, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Haowei</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Laboratory of Animal Neurobiology, College of Veterinary Medicine, Nanjing Agricultural University, Nanjing, 210095, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ping</LastName><ForeName>Jihui</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>MOE Joint International Research Laboratory of Animal Health and Food Safety, Engineering Laboratory of Animal Immunity of Jiangsu Province, College of Veterinary Medicine, Nanjing Agricultural University, Nanjing, 210095, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qiao</LastName><ForeName>Wenna</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Laboratory of Animal Neurobiology, College of Veterinary Medicine, Nanjing Agricultural University, Nanjing, 210095, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Su</LastName><ForeName>Juan</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-6239-1711</Identifier><AffiliationInfo><Affiliation>Laboratory of Animal Neurobiology, College of Veterinary Medicine, Nanjing Agricultural University, Nanjing, 210095, China. sujuan@njau.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>32272992</GrantID><Agency>National Natural Science Foundation of China</Agency><Country /></Grant><Grant><GrantID>GC2021003</GrantID><Agency>Xinjiang Animal Disease Prevention and Control Engineering Technology Research Center</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Appl Microbiol Biotechnol</MedlineTA><NlmUniqueID>8406612</NlmUniqueID><ISSNLinking>0175-7598</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>L36O5T016N</RegistryNumber><NameOfSubstance UI="D000078262">Rifaximin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012336">RNA, Ribosomal, 16S</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007378">Interleukins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000097043">Interleukin-22</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050796">STAT3 Transcription Factor</NameOfSubstance></Chemical><Chemical><RegistryNumber>8DUH1N11BX</RegistryNumber><NameOfSubstance UI="D014364">Tryptophan</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069196" MajorTopicYN="Y">Gastrointestinal Microbiome</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000078262" MajorTopicYN="Y">Rifaximin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008168" MajorTopicYN="Y">Lung</DescriptorName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009976" MajorTopicYN="Y">Orthomyxoviridae Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009980" MajorTopicYN="Y">Influenza A virus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012336" MajorTopicYN="N">RNA, Ribosomal, 16S</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007378" MajorTopicYN="N">Interleukins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000097043" MajorTopicYN="N">Interleukin-22</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050796" MajorTopicYN="N">STAT3 Transcription Factor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005243" MajorTopicYN="N">Feces</DescriptorName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014364" MajorTopicYN="N">Tryptophan</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055370" MajorTopicYN="N">Lung Injury</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019936" MajorTopicYN="N">Probiotics</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Gut-lung axis</Keyword><Keyword MajorTopicYN="N">ILC3 cell</Keyword><Keyword MajorTopicYN="N">Influenza A virus</Keyword><Keyword MajorTopicYN="N">Rifaximin</Keyword><Keyword MajorTopicYN="N">Tryptophan metabolism</Keyword></KeywordList><CoiStatement>The authors have declared no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>12</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>7</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>21</Day><Hour>13</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>21</Day><Hour>13</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>19</Day><Hour>11</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39298023</ArticleId><ArticleId IdType="pmc">PMC11413070</ArticleId><ArticleId IdType="doi">10.1007/s00253-024-13280-6</ArticleId><ArticleId IdType="pii">10.1007/s00253-024-13280-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ardain A, Porterfield JZ, Kloverpris HN, Leslie A (2019) Type 3 ILCs in lung disease. Front Immunol 10:92. 10.3389/fimmu.2019.00092</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6361816</ArticleId><ArticleId IdType="pubmed">30761149</ArticleId></ArticleIdList></Reference><Reference><Citation>Barthelemy A, Sencio V, Soulard D, Deruyter L, Faveeuw C, Le Goffic R, Trottein F (2018) Interleukin-22 immunotherapy during severe influenza enhances lung tissue integrity and reduces secondary bacterial systemic invasion. Infect Immun 86(7). 10.1128/IAI.00706-17</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6013680</ArticleId><ArticleId IdType="pubmed">29661933</ArticleId></ArticleIdList></Reference><Reference><Citation>Cervantes-Barragan L, Chai JN, Tianero MD, Di Luccia B, Ahern PP, Merriman J, Cortez VS, Caparon MG, Donia MS, Gilfillan S, Cella M, Gordon JI, Hsieh CS, Colonna M (2017) Lactobacillus reuteri induces gut intraepithelial CD4(+)CD8α(+) T cells. Science 357(6353):806–810. 10.1126/science.aah5825</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5687812</ArticleId><ArticleId IdType="pubmed">28775213</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Jiang Z, Lei Z, Ping J, Su J (2021) Effect of rifaximin on gut-lung axis in mice infected with influenza A virus. Comp Immunol Microbiol Infect Dis 75:101611. 10.1016/j.cimid.2021.101611</Citation><ArticleIdList><ArticleId IdType="pubmed">33503578</ArticleId></ArticleIdList></Reference><Reference><Citation>Dumas A, Bernard L, Poquet Y, Lugo-Villarino G, Neyrolles O (2018) The role of the lung microbiota and the gut-lung axis in respiratory infectious diseases. Cell Microbiol 20(12):e12966. 10.1111/cmi.12966</Citation><ArticleIdList><ArticleId IdType="pubmed">30329198</ArticleId></ArticleIdList></Reference><Reference><Citation>DuPont HL (2016a) Introduction: understanding mechanisms of the actions of rifaximin in selected gastrointestinal diseases. Aliment Pharmacol Ther 43(Suppl 1):1–2. 10.1111/apt.13406</Citation><ArticleIdList><ArticleId IdType="pubmed">26618920</ArticleId></ArticleIdList></Reference><Reference><Citation>DuPont HL (2016b) Review article: the antimicrobial effects of rifaximin on the gut microbiota. Aliment Pharmacol Ther 43(Suppl 1):3–10. 10.1111/apt.13434</Citation><ArticleIdList><ArticleId IdType="pubmed">26618921</ArticleId></ArticleIdList></Reference><Reference><Citation>Gatta L, Scarpignato C (2017) Systematic review with meta-analysis: rifaximin is effective and safe for the treatment of small intestine bacterial overgrowth. Aliment Pharmacol Ther 45(5):604–616. 10.1111/apt.13928</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5299503</ArticleId><ArticleId IdType="pubmed">28078798</ArticleId></ArticleIdList></Reference><Reference><Citation>Gronke K, Hernandez PP, Zimmermann J, Klose CSN, Kofoed-Branzk M, Guendel F, Witkowski M, Tizian C, Amann L, Schumacher F, Glatt H, Triantafyllopoulou A, Diefenbach A (2019) Interleukin-22 protects intestinal stem cells against genotoxic stress. Nature 566(7743):249–253. 10.1038/s41586-019-0899-7</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6420091</ArticleId><ArticleId IdType="pubmed">30700914</ArticleId></ArticleIdList></Reference><Reference><Citation>Groves HT, Cuthbertson L, James P, Moffatt MF, Cox MJ, Tregoning JS (2018) Respiratory disease following viral lung infection alters the murine gut microbiota. Front Immunol 9:182. 10.3389/fimmu.2018.00182</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5816042</ArticleId><ArticleId IdType="pubmed">29483910</ArticleId></ArticleIdList></Reference><Reference><Citation>Hause BM, Collin EA, Liu R, Huang B, Sheng Z, Lu W, Wang D, Nelson EA, Li F (2014) Characterization of a novel influenza virus in cattle and swine: proposal for a new genus in the Orthomyxoviridae family. mBio 5(2):e00031-14. 10.1128/mBio.00031-14</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3958797</ArticleId><ArticleId IdType="pubmed">24595369</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang J, Liu D, Wang Y, Liu L, Li J, Yuan J, Jiang Z, Jiang Z, Hsiao WW, Liu H, Khan I, Xie Y, Wu J, Xie Y, Zhang Y, Fu Y, Liao J, Wang W, Lai H, Shi A, Cai J, Luo L, Li R, Yao X, Fan X, Wu Q, Liu Z, Yan P, Lu J, Yang M, Wang L, Cao Y, Wei H, Leung EL (2022) Ginseng polysaccharides alter the gut microbiota and kynurenine/tryptophan ratio, potentiating the antitumour effect of antiprogrammed cell death 1/programmed cell death ligand 1 (anti-PD-1/PD-L1) immunotherapy. Gut 71(4):734–745. 10.1136/gutjnl-2020-321031</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8921579</ArticleId><ArticleId IdType="pubmed">34006584</ArticleId></ArticleIdList></Reference><Reference><Citation>Keely S, Talley NJ, Hansbro PM (2012) Pulmonary-intestinal cross-talk in mucosal inflammatory disease. Mucosal Immunol 5(1):7–18. 10.1038/mi.2011.55</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3243663</ArticleId><ArticleId IdType="pubmed">22089028</ArticleId></ArticleIdList></Reference><Reference><Citation>Kenney AD, McMichael TM, Imas A, Chesarino NM, Zhang L, Dorn LE, Wu Q, Alfaour O, Amari F, Chen M, Zani A, Chemudupati M, Accornero F, Coppola V, Rajaram MVS, Yount JS (2019) IFITM3 protects the heart during influenza virus infection. Proc Natl Acad Sci U S A 116(37):18607–18612. 10.1073/pnas.1900784116</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6744864</ArticleId><ArticleId IdType="pubmed">31451661</ArticleId></ArticleIdList></Reference><Reference><Citation>Kepert I, Fonseca J, Müller C, Milger K, Hochwind K, Kostric M, Fedoseeva M, Ohnmacht C, Dehmel S, Nathan P, Bartel S, Eickelberg O, Schloter M, Hartmann A, Schmitt-Kopplin P, Krauss-Etschmann S (2017) D-tryptophan from probiotic bacteria influences the gut microbiome and allergic airway disease. J Allergy Clin Immunol 139(5):1525–1535. 10.1016/j.jaci.2016.09.003</Citation><ArticleIdList><ArticleId IdType="pubmed">27670239</ArticleId></ArticleIdList></Reference><Reference><Citation>Kudva A, Scheller EV, Robinson KM, Crowe CR, Choi SM, Slight SR, Khader SA, Dubin PJ, Enelow RI, Kolls JK, Alcorn JF (2011) Influenza A inhibits Th17-mediated host defense against bacterial pneumonia in mice. J Immunol 186(3):1666–1674. 10.4049/jimmunol.1002194</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4275066</ArticleId><ArticleId IdType="pubmed">21178015</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L, Chen G, Huang S, Wen F (2023) Receptor binding properties of neuraminidase for influenza a virus: an overview of recent research advances. Virulence 14(1):2235459. 10.1080/21505594.2023.2235459</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10361132</ArticleId><ArticleId IdType="pubmed">37469130</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu H, Zhang L, Xiao J, Wu C, Zhang H, Chen Y, Hu Z, Lin W, Xie Q, Li H (2019) Effect of feeding Chinese herb medicine ageratum-liquid on intestinal bacterial translocations induced by H9N2 AIV in mice. Virol J 16(1):24. 10.1186/s12985-019-1131-y</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6385471</ArticleId><ArticleId IdType="pubmed">30791956</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo M, Xie P, Deng X, Fan J, Xiong L (2023) Rifaximin ameliorates loperamide-induced constipation in rats through the regulation of gut microbiota and serum metabolites. Nutrients 15(21):4502. 10.3390/nu15214502</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10648458</ArticleId><ArticleId IdType="pubmed">37960154</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinu T, McManigle WC, Kelly FL, Nelson ME, Sun J, Zhang HL, Kolls JK, Gowdy KM, Palmer SM (2019) IL-17A contributes to lung fibrosis in a model of chronic pulmonary graft-versus-host disease. Transplantation 103(11):2264–2274. 10.1097/TP.0000000000002837</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7550218</ArticleId><ArticleId IdType="pubmed">31658231</ArticleId></ArticleIdList></Reference><Reference><Citation>Merga Y, Campbell BJ, Rhodes JM (2014) Mucosal barrier, bacteria and inflammatory bowel disease: possibilities for therapy. Dig Dis 32(4):475–483. 10.1159/000358156</Citation><ArticleIdList><ArticleId IdType="pubmed">24969297</ArticleId></ArticleIdList></Reference><Reference><Citation>Mortha A, Chudnovskiy A, Hashimoto D, Bogunovic M, Spencer SP, Belkaid Y, Merad M (2014) Microbiota-dependent crosstalk between macrophages and ILC3 promotes intestinal homeostasis. Science 343(6178):1249288. 10.1126/science.1249288</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4291125</ArticleId><ArticleId IdType="pubmed">24625929</ArticleId></ArticleIdList></Reference><Reference><Citation>Ojetti V, Lauritano EC, Barbaro F, Migneco A, Ainora ME, Fontana L, Gabrielli M, Gasbarrini A (2009) Rifaximin pharmacology and clinical implications. Expert Opin Drug Metab Toxicol 5(6):675–682. 10.1517/17425250902973695</Citation><ArticleIdList><ArticleId IdType="pubmed">19442033</ArticleId></ArticleIdList></Reference><Reference><Citation>Peteranderl C, Herold S, Schmoldt C (2016) Human influenza virus infections. Semin Respir Crit Care Med 37(4):487–500. 10.1055/s-0036-1584801</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7174870</ArticleId><ArticleId IdType="pubmed">27486731</ArticleId></ArticleIdList></Reference><Reference><Citation>Sonnenberg GF, Fouser LA, Artis D (2011a) Border patrol: regulation of immunity, inflammation and tissue homeostasis at barrier surfaces by IL-22. Nat Immunol 12(5):383–390. 10.1038/ni.2025</Citation><ArticleIdList><ArticleId IdType="pubmed">21502992</ArticleId></ArticleIdList></Reference><Reference><Citation>Sonnenberg GF, Monticelli LA, Elloso MM, Fouser LA, Artis D (2011b) CD4(+) lymphoid tissue-inducer cells promote innate immunity in the gut. Immunity 34(1):122–134. 10.1016/j.immuni.2010.12.009</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3035987</ArticleId><ArticleId IdType="pubmed">21194981</ArticleId></ArticleIdList></Reference><Reference><Citation>Swaim CD, Canadeo LA, Monte KJ, Khanna S, Lenschow DJ, Huibregtse JM (2020) Modulation of extracellular isg15 signaling by pathogens and viral effector proteins. Cell Rep 31(11):107772. 10.1016/j.celrep.2020.107772</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7297157</ArticleId><ArticleId IdType="pubmed">32553163</ArticleId></ArticleIdList></Reference><Reference><Citation>Uribe-Herranz M, Bittinger K, Rafail S, Guedan S, Pierini S, Tanes C, Ganetsky A, Morgan MA, Gill S, Tanyi JL, Bushman FD, June CH, Facciabene A (2018) Gut microbiota modulates adoptive cell therapy via CD8α dendritic cells and IL-12. JCI insight 3(4). 10.1172/jci.insight.94952</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5916241</ArticleId><ArticleId IdType="pubmed">29467322</ArticleId></ArticleIdList></Reference><Reference><Citation>Venkatesh M, Mukherjee S, Wang H, Li H, Sun K, Benechet AP, Qiu Z, Maher L, Redinbo MR, Phillips RS, Fleet JC, Kortagere S, Mukherjee P, Fasano A, Le Ven J, Nicholson JK, Dumas ME, Khanna KM, Mani S (2014) Symbiotic bacterial metabolites regulate gastrointestinal barrier function via the xenobiotic sensor PXR and Toll-like receptor 4. Immunity 41(2):296–310. 10.1016/j.immuni.2014.06.014</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4142105</ArticleId><ArticleId IdType="pubmed">25065623</ArticleId></ArticleIdList></Reference><Reference><Citation>Waheed AA, Freed EO (2007) Influenza virus not cRAFTy enough to dodge viperin. Cell Host Microbe 2(2):71–72. 10.1016/j.chom.2007.07.005</Citation><ArticleIdList><ArticleId IdType="pubmed">18005719</ArticleId></ArticleIdList></Reference><Reference><Citation>Wlodarska M, Luo C, Kolde R, d’Hennezel E, Annand JW, Heim CE, Krastel P, Schmitt EK, Omar AS, Creasey EA, Garner AL, Mohammadi S, O’Connell DJ, Abubucker S, Arthur TD, Franzosa EA, Huttenhower C, Murphy LO, Haiser HJ, Vlamakis H, Porter JA, Xavier RJ (2017) Indoleacrylic acid produced by commensal peptostreptococcus species suppresses inflammation. Cell Host Microbe 22(1):25-37.e6. 10.1016/j.chom.2017.06.007</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5672633</ArticleId><ArticleId IdType="pubmed">28704649</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang D, Li S, Wang N, Tan HY, Zhang Z, Feng Y (2020) The cross-talk between gut microbiota and lungs in common lung diseases. Front Microbiol 11:301. 10.3389/fmicb.2020.00301</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7052046</ArticleId><ArticleId IdType="pubmed">32158441</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J, Zhu S, Ma N, Johnston LJ, Wu C, Ma X (2021) Metabolites of microbiota response to tryptophan and intestinal mucosal immunity: a therapeutic target to control intestinal inflammation. Med Res Rev 41(2):1061–1088. 10.1002/med.21752</Citation><ArticleIdList><ArticleId IdType="pubmed">33174230</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>